Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2160 (LINC02160) is an autonomously transcribed RNA gene longer than 200 nucleotides that does not overlap annotated coding genes. It belongs to the class of long intergenic non-coding RNAs (lincRNAs), which are known in general to regulate chromatin structure, transcription, and genome architecture, typically with high tissue specificity[5][1][3]. There is no specific data regarding LINC02160's function, clinical utility, therapeutic targeting, or disease association. Like many lincRNAs, its biological roles are inferred from its molecular class—possible regulation of neighboring genes, modulation of chromatin and transcription, and involvement in fine-tuning gene expression[5]. LINC02160 is cataloged in major gene databases (GeneCards, BioGPS, NCBI Gene), but its functional characterization and clinical relevance remain unknown[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2160 (LINC02160).